Stroke
Conditions
Brief summary
This study will explore the effect of warfarin gene polymorphism on the effectiveness and safety of anticoagulant therapy in patients with acute ischemic stroke, and clarify the correlation between genetic testing and compliance rate of INR value. It will illustrate the significance of gene-guided warfarin for administered dose to anticoagulation therapy in patients with acute ischemic stroke. Then it will establish and verify a warfarin stable dose prediction model suitable for such patients, and provide basis for the personalized medication regimen of warfarin in patients with acute ischemic stroke.
Interventions
DEVICEGene detection (CYP2C9*3, VKORC1)
Warfarin is administered at the recommended dose by detecting CYP2C9\*3 and VKORC1 gene polymorphismsand. The doctor adjusts the dosage according to the fluctuation of INR value in time.
DRUGWarfarin Sodium
Warfarin is administered at a gene-guided dose or at a regular dose.
Sponsors
First Affiliated Hospital Xi'an Jiaotong University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Caregiver)
Eligibility
Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
No
Inclusion criteria
* Patients with acute ischemic stroke aged ≥18 years (cardiogenic cerebral embolism patients) * Clinicians judge that long-term oral anticoagulation with warfarin is required * No anticoagulation treatment in the past 10 days * Agree to participate in this project
Exclusion criteria
* Patients who had a tendency to bleed when taking warfarin * High-risk groups using warfarin anticoagulation
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Stroke recurrence rate, compliance rate of INR value | 12 months | Evaluation and analysis of the stroke recurrence rate and compliance rate of INR value at 12 months after treatment |
Outcome results
None listed